Compositions and method for treating precancerous virus infection and prevention of cancer

Abstract

An anti-cancer composition having biocompatible materials, which can selectively exploit chemical variations between normal cells and cancer cells to inhibit or prevent the proliferation of cancerous cells and methods of use.

1 - 107 . (canceled)  
     
     
         108 . A composition for use as a pharmaceutical for targeting at least one pre-cancerous affecting virus, for prevention of cancer comprising: a core essentially of biologically acceptable fixed copper compound, and a sheath that encapsulates the biologically acceptable fixed copper compound.  
     
     
         109 . The composition as in  claim 108  where said virus is a hepatocellular affecting virus and said cancer is liver cancer.  
     
     
         110 . The composition of  claim 108 , wherein the composition is used for therapeutic treatment of hepatitis B virus.  
     
     
         111 . The composition of  claim 108 , wherein the composition is used for preventive pre-acute stage treatment of hepatitis B viral infection.  
     
     
         112 . The composition of  claim 108 , wherein the composition is used for therapeutic treatment of hepatitis C virus.  
     
     
         113 . The composition of  claim 108 , wherein the composition is used for preventive pre-acute stage treatment of hepatitis C viral infection.  
     
     
         114 . The composition as in  claim 108  wherein said virus is human papilloma virus (HPV) and said cancer is cervical cancer.  
     
     
         115 . The composition as in  claim 108  wherein said virus is Epstein-Barr Virus (EBV) and said cancer is Burkitt's lymphoma.  
     
     
         116 . The composition as in  claim 108  wherein said virus is Human T-cell Lymphotropic Virus (HTLV-1) and said cancer is Adult T-cell Leukemia/Lymphoma.  
     
     
         117 . The composition of  claim 108 , wherein the sheath is formed of a material selected from the group consisting essentially of lipids, polypeptides, oligopeptides, polynucleotides, proteins, liposomes and combinations thereof.  
     
     
         118 . The composition of  claim 108 , wherein the sheath is formed of a material selected from the group consisting essentially of a glucose, a saccharide, a polysaccharide, a dextran, liposomes, derivatives and combinations thereof.  
     
     
         119 . The composition of claims  108 , wherein a liposome coat encapsulates the sheath.  
     
     
         120 . The composition of  claim 108 , wherein a polysaccharide sheath encapsulates the composition.  
     
     
         121 . The composition of  claim 108 , wherein the biologically acceptable fixed copper compound is selected from the group consisting of copper hydroxide, copper oxide, copper oxychloride, copper carbonate basic, copper sulfate, copper-iron hydroxide, copper-iron oxide, copper-iron oxyhydroxide, copper sulfate basic, cuprous oxide, cupric hydroxide-iron hydroxide, cupric citrate, cupric glycinate, cupric gluconate, cupric phosphate, cuprobam, cupric salicylite, indigo copper, cupro-cupric sulfate, cuprous sulfate, cuprous sulfate hemihydrite, brochantite, langite, malachite, azurite, cheesylite, cornetite, dihydyrite, libethenite, phosphorochalcite, pseudolibethenite, pseudo-malachite, tagilite, antlerite, covellite, marshite, cuprite, chalcocite, Rogojski's salt, brochantite, hydrocyanite, chalcanthtite, nantokite and dolerophane.  
     
     
         122 . A chemical composition for use in targeting at least one pre-cancerous affecting virus, for prevention of cancer comprising: a core essentially of a fixed copper-iron compound, and a sheath that encapsulates the core of the copper-iron compound.  
     
     
         123 . The composition as in  claim 122  where said virus is a hepatocellular affecting virus and said cancer is liver cancer.  
     
     
         124 . The composition of  claim 122 , wherein the composition is used for therapeutic treatment of hepatitis B virus.  
     
     
         125 . The composition of  claim 122 , wherein the composition is used for preventive pre-acute stage treatment of hepatitis B viral infection.  
     
     
         126 . The composition of  claim 122 , wherein the composition is used for therapeutic treatment of hepatitis C virus.  
     
     
         127 . The composition of  claim 122 , wherein the composition is used for preventive pre-acute stage treatment of hepatitis C viral infection.  
     
     
         128 . The composition as in  claim 122 , wherein said virus is human papilloma virus (HPV) and said cancer is cervical cancer.  
     
     
         129 . The composition as in  claim 122 , wherein said virus is Epstein-Barr Virus (EBV) and said cancer is Burkitt's lymphoma.  
     
     
         130 . The composition as in  claim 122 , wherein said virus is Human T-cell Lymphotropic Virus (HTLV-1) and said cancer is Adult T-cell Leukemia/Lymphoma.  
     
     
         131 . The composition of  claim 122 , wherein the sheath is formed of a material selected from the group consisting essentially of a glucose, a saccharide, a polysaccharide, a dextran, liposomes, derivatives and combinations thereof.  
     
     
         132 . The composition of  claim 122 , wherein the sheath is formed of a material selected from the group consisting essentially of lipids, polypeptides, oligopeptides, polynucleotides, proteins, and combinations thereof.  
     
     
         133 . The composition of claims  122 , wherein a liposome coat encapsulates the sheath.  
     
     
         134 . The composition of  claim 122 , wherein the fixed copper-iron compound core is copper hydroxide-iron hydroxide.  
     
     
         135 . The composition of  claim 122 , wherein said fixed copper-iron compound core is copper hydroxide-iron oxide.  
     
     
         136 . The composition of  claim 122 , wherein said fixed copper-iron compound core is copper-iron oxyhydroxide.  
     
     
         137 . The composition of  claim 122 , wherein the core particle is targeted with a targeting agent.  
     
     
         138 . The composition of  claim 122 , wherein the core particle is targeted with a marker.  
     
     
         139 . The composition of  claim 122 , wherein the core particle is targeted with magnetic particles.  
     
     
         140 . A chemical composition for targeting at least one pre-cancerous affecting virus, for prevention of cancer comprising: a compound of synergistic components of a fixed copper and iron to form a core particle.  
     
     
         141 . The composition as in  claim 140  where said virus is a hepatocellular affecting virus and said cancer is liver cancer.  
     
     
         142 . The composition of  claim 140 , wherein the composition is used for therapeutic treatment of hepatitis B virus.  
     
     
         143 . The composition of  claim 140 , wherein the composition is used for preventive pre-acute stage treatment of hepatitis B viral infection.  
     
     
         144 . The composition of  claim 140 , wherein the composition is used for therapeutic treatment of hepatitis C virus.  
     
     
         145 . The composition of  claim 140 , wherein the composition is used for preventive pre-acute stage treatment of hepatitis C viral infection.  
     
     
         146 . The composition as in  claim 140  wherein said virus is human papilloma virus (HPV) and said cancer is cervical cancer.  
     
     
         147 . The composition as in  claim 140  wherein said virus is Epstein-Barr Virus (EBV) and said cancer is Burkitt's lymphoma.  
     
     
         148 . The composition as in  claim 140  wherein said virus is Human T-cell Lymphotropic Virus (HTLV-1) and said cancer is Adult T-cell Leukemia/Lymphoma.  
     
     
         149 . The composition of  claim 140 , wherein the copper of the core particle is selected from the group consisting of copper hydroxide, copper oxide, copper oxychloride, copper carbonate basic, copper sulfate, copper-iron hydroxide, copper-iron oxide, copper-iron oxyhydroxide, copper sulfate basic, cuprous oxide, cupric hydroxide-iron hydroxide, cupric citrate, cupric glycinate, cupric gluconate, cupric phosphate, cuprobam, cupric salicylite, indigo copper, cupro-cupric sulfate, cuprous sulfate, cuprous sulfate hemihydrite, brochantite, langite, malachite, azurite, cheesylite, cornetite, dihydyrite, libethenite, phosphorochalcite, pseudolibethenite, pseudo-malachite, tagilite, antlerite, covellite, marshite, cuprite, chalcocite, Rogojski's salt, brochantite, hydrocyanite, chalcanthtite, nantokite and dolerophane.  
     
     
         150 . The composition of  claim 140 , wherein the iron of the core particle is iron hydroxide.  
     
     
         151 . The composition of  claim 140 , wherein the iron of the core particle is iron oxide.  
     
     
         152 . The composition of  claim 140 , wherein the iron of the core particle is an iron compound.  
     
     
         153 . The composition of  claim 140 , wherein the core particle is encapsulated with a sheath.  
     
     
         154 . The composition of  claim 140 , wherein the core particle is coated with liposomes.  
     
     
         155 . The composition of  claim 140 , wherein the core particle is targeted with a targeting agent.  
     
     
         156 . The composition of  claim 140 , wherein the core particle is targeted with a marker.  
     
     
         157 . The composition of  claim 140 , wherein the core particle is targeted with magnetic particles.  
     
     
         158 . A composition for medicinal use in mammals comprising: a biologically acceptable, fixed copper compound core, and said fixed copper compound core being encapsulated, encoated, adsorbed, complexed or bound in at least one of a sheath, a shell, a polymeric shell, a cover, a casing, an encoating, a jacket or combination thereof, and a pharmaceutically acceptable carrier, said sheath, shell, polymeric shell, cover, casing, encoating, jacket or combination thereof being made of a material targeting at least one pre-cancerous affecting virus, and preventing immediate chemical interaction of the core with the surrounding cellular environment; said fixed copper compound core further comprising a material that remains in circulation of the mammals, wherein said targeting of said virus is used for prevention of cancer.  
     
     
         159 . The composition as in  claim 158  where said virus is a hepatocellular affecting virus and said cancer is liver cancer.  
     
     
         160 . The composition of  claim 158 , wherein the composition is used for therapeutic treatment of hepatitis B virus.  
     
     
         161 . The composition of  claim 158 , wherein the composition is used for preventive pre-acute stage treatment of hepatitis B viral infection.  
     
     
         162 . The composition of  claim 158 , wherein the composition is used for therapeutic treatment of hepatitis C virus.  
     
     
         163 . The composition of  claim 158 , wherein the composition is used for preventive pre-acute stage treatment of hepatitis C viral infection.  
     
     
         164 . The composition of  claim 158 , wherein the composition is used for therapeutic treatment of pre-cancerous viral infection.  
     
     
         165 . The composition of  claim 158 , wherein the composition is used for destroying Hepatitis B virus particles in a mammal infected with Hepatitis B prior to the onset of liver cancer in said infected mammal.  
     
     
         166 . The composition of  claim 158 , wherein the composition is used for destroying Hepatitis C virus particles in a mammal infected with Hepatitis C prior to the onset of liver cancer in said infected mammal.  
     
     
         167 . The composition as in  claim 158  wherein said virus is human papilloma virus (HPV) and said cancer is cervical cancer.  
     
     
         168 . The composition as in  claim 158  wherein said virus is Epstein-Barr Virus and said cancer is Burkitt's lymphoma.  
     
     
         169 . The composition as in  claim 158  wherein said virus is Human T-cell Lymphotropic Virus (HTLV-1) and said cancer is Adult T-cell Leukemia/Lymphoma.  
     
     
         170 . A chemical composition for treating at least one pre-cancerous affecting virus causing cancer in mammals comprising: a compound of synergistic components of a fixed compound of copper and iron to form a core particle, said core particle targeting said virus without affecting the surrounding environment.  
     
     
         171 . The composition as in  claim 170  where said virus is a hepatocellular affecting virus and said cancer is liver cancer.  
     
     
         172 . The composition as in  claim 170  wherein said affecting virus is selected from the group consisting of Hepatitis B virus and Hepatitis C virus.  
     
     
         173 . The composition as in  claim 170  wherein said virus is human papilloma virus (HPV) and said cancer is cervical cancer.  
     
     
         174 . The composition as in  claim 170  wherein said virus is Epstein-Barr Virus (EBV) and said cancer is Burkitt's lymphoma.  
     
     
         175 . The composition as in  claim 170  wherein said virus is Human T-cell Lymphotropic Virus (HTLV-1) and said cancer is Adult T-cell Leukemia/Lymphoma.  
     
     
         176 . A method for treating precancerous Virus infection and prevention of cancer in a patient comprising: forming a colloidal solution composition of at least a fixed copper compound core, and said fixed copper compound core being encapsulated, encoated, adsorbed, complexed or bound in at least one of a sheath, a shell, a polymeric shell, a cover, a casing, an encoating, a jacket or combination thereof, and a pharmaceutically acceptable carrier, said sheath, shell, polymeric shell, cover, casing, encoating, jacket or combination thereof being made of a material targeting at least one precancerous virus, and preventing immediate chemical interaction of the core with the surrounding cellular environment; said fixed copper compound core further comprising a material that remains in circulation of the mammals, wherein said targeting of said virus is used for prevention of cancer.  
     
     
         177 . The composition as in  claim 176  where said virus is a hepatocellular affecting virus and said cancer is liver cancer.  
     
     
         178 . The method for treating precancerous hepatocellular Virus infection and prevention of liver cancer of  claim 176 , wherein the composition is used for therapeutic treatment of hepatitis B virus.  
     
     
         179 . The method for treating precancerous hepatocellular Virus infection and prevention of liver cancer of  claim 176 , wherein the composition is used for preventive pre-acute stage treatment of hepatitis B viral infection.  
     
     
         180 . The method for treating precancerous hepatocellular Virus infection and prevention of liver cancer of  claim 176 , wherein the composition is used for therapeutic treatment of hepatitis C virus.  
     
     
         181 . The method for treating precancerous hepatocellular Virus infection and prevention of liver cancer of  claim 176 , wherein the composition is used for preventive pre-acute stage treatment of hepatitis C viral infection.  
     
     
         182 . The method for treating precancerous hepatocellular Virus infection and prevention of liver cancer of  claim 176 , wherein the composition is used for therapeutic treatment of pre-cancerous viral infection.  
     
     
         183 . The method for treating precancerous hepatocellular Virus infection and prevention of liver cancer of  claim 176 , wherein the composition is used for destroying Hepatitis B virus particles in a mammal infected with Hepatitis B prior to the onset of liver cancer in said infected mammal.  
     
     
         184 . The method for treating precancerous hepatocellular Virus infection and prevention of liver cancer of  claim 176 , wherein the composition is used for destroying Hepatitis C virus particles in a mammal infected with Hepatitis C prior to the onset of liver cancer in said infected mammal.  
     
     
         185 . The composition as in  claim 176  wherein said virus is human papilloma virus (HPV) and said cancer is cervical cancer.  
     
     
         186 . The composition as in  claim 176  wherein said virus is Epstein-Barr Virus (EBV) and said cancer is Burkitt's lymphoma.  
     
     
         187 . The composition as in  claim 176  wherein said virus is Human T-cell Lymphotropic Virus (HTLV-1) and said cancer is Adult T-cell Leukemia/Lymphoma.  
     
     
         188 . The method of  claim 176  further comprising the steps of administering the colloidal solution composition to a patient; monitoring the presence of said hepatocellular virus in the patient; and re-administering the composition at intervals based on results of the monitoring.  
     
     
         189 . A method for treating an affecting virus and preventing cancer comprising the steps of administering a compound of synergistic components of fixed copper and fixed iron to a patient infecting with at least one pre-cancerous virus.  
     
     
         190 . The composition as in  claim 189  where said virus is a hepatocellular affecting virus and said cancer is liver cancer.  
     
     
         191 . The method as in  claim 189  wherein said hepatocellular affecting virus is selected from the group consisting of Hepatitis B virus and Hepatitis C virus.  
     
     
         192 . The composition as in  claim 189  wherein said virus is human papilloma virus (HPV) and said cancer is cervical cancer.  
     
     
         193 . The composition as in  claim 189  wherein said virus is Epstein-Barr Virus (EBV) and said cancer is Burkitt's lymphoma.  
     
     
         194 . The composition as in  claim 189  wherein said virus is Human T-cell Lymphotropic Virus (HTLV-1) and said cancer is Adult T-cell Leukemia/Lymphoma.